Archive · 18 Sep 2026
Lords Mark Industries Hits Upper Circuit After Expansion Update
Lords Mark Industries makes products and services related to healthcare and renewable energy.
Its share price rose to ₹89.68 after the company announced a business update.
The company said it finished the first part of an expansion at its Silvassa facility earlier than planned.
It also increased its surgical and orthopaedic product range from 36 items to 54.
The new production line is expected to start working on 11 October.
The company said its older products already have US FDA approval.
The 18 new products are still going through the approval process.
Lords Mark Industries also said it has a renewable-energy order pipeline worth more than ₹3,000 crore and wants to expand its healthcare network.
Lords Mark Industries shares rose 5% to ₹89.68 on 18 September, marking gains of more than 10% over three sessions.
The company said it completed phase one of its Silvassa expansion nearly three months ahead of its December 2026 commitment.
Its surgical and orthopaedic portfolio expanded from 36 to 54 products, adding 18 new stock-keeping units.
The expanded production line is scheduled to begin commercial operations on 11 October.
The company also cited a renewable-energy order pipeline exceeding ₹3,000 crore and plans for major healthcare expansion by 2028.
- Who
- Lords Mark Industries and its shareholders.
- What
- The company announced expansion progress, a larger medical-device portfolio, and other growth plans; its shares reached the 5% upper circuit.
- When
- The business update was filed on 16 September, and the share-price move occurred on Friday, 18 September. Commercial operations are scheduled for 11 October.
- Where
- The expansion is at the company’s Silvassa facility; its broader plans cover India and international markets.
- Why
- The company said the expansion is intended to increase manufacturing capacity, broaden market reach, and support its medical-devices growth plans.
- Share price
- ₹89.68 after a 5% upper-circuit move
- Three-session gain
- More than 10%
- Expansion status
- Phase one at the Silvassa facility was completed nearly three months ahead of the December 2026 commitment
- Product portfolio
- Surgical and orthopaedic products increased from 36 to 54 SKUs
- Commercial launch
- The expanded production line is scheduled to begin operations on 11 October
- Renewable-energy pipeline
- More than ₹3,000 crore
- Healthcare targets
- More than 2,000 pathology labs and 1,000 renal care units by March 2028